US PTAB Patent Cases
8,722 decisions indexed
Page 75 of 291 · 8,722 total
Samsung Electronics Co., Ltd. et al. v.SnapAid Ltd.
Samsung Electronics has filed an IPR petition seeking cancellation of all 20 claims of SnapAid’s ’901 patent on grounds of obviousness under 35 U.S.C. §103, citing a suite of prior‑art references covering image‑quality assessment and camera feedback systems.
BOE Technology Group Co., Ltd. v.138 East LCD Advancements Limited et al.
BOE has filed an IPR petition challenging all 13 claims of U.S. Patent 8,391,020, asserting that the claimed LCD wiring configurations were already known in Takenaka, Ito, and Takemura publications, making the claims obvious under §103.
Samsung Electronics Co. Ltd. et al. v.Maxell, LTD.
Samsung Electronics petitions the PTAB to invalidate 20 claims of Maxell’s ’091 set‑top‑box patent, asserting obviousness over multiple prior‑art references. The petition lists six grounds covering all claims and cites expert testimony to bolster its position.
Samsung Electronics Co., Ltd. et al. v.SnapAid Ltd.
Samsung has filed an IPR petition seeking cancellation of all 20 claims of SnapAid’s ’702 patent on the ground of obviousness under 35 U.S.C. §103, citing multiple prior‑art camera‑technology references.
Samsung Electronics Co. Ltd. et al. v.Maxell, LTD.
The Board granted institution for IPR2025-01311, allowing the challenge to proceed to merits review after determining the petitioner met the required likelihood of success standard.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Samsung (on behalf of Apple) petitions the PTAB to invalidate Omni MedSci’s ’533 wearable health‑monitoring patent. The petition asserts that the claims are obvious over Lisogurski, Carlson, and Mannheimer references. No secondary considerations are presented.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple seeks to invalidate Omni MedSci’s ’484 wearable health‑monitoring patent, arguing the claims are obvious over a combination of prior‑art references. The petition requests the PTAB to institute the review and find all claims unpatentable.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple petitions to invalidate Omni MedSci’s ’484 wearable health‑monitoring patent, asserting obviousness over five prior‑art references. The petition seeks institution of an IPR to cancel all 23 claims.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple succeeded in invalidating Omni MedSci's wearable physiological measurement patent, with the PTAB finding all challenged claims obvious over prior art.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple prevailed in an IPR against Omni MedSci’s wearable health‑monitoring patent, finding claims 1, 2, 7 and 15‑23 unpatentable while leaving claims 3‑6 and 8‑14 intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR of Omni MedSci’s 9,651,533 patent was decided with all challenged claims found unpatentable under §103, based on obviousness over Lisogurski, Carlson, and Mannheimer prior art.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s ‘299 patent was decided with all challenged claims (7, 10‑14) found unpatentable as obvious over Lisogurski, Carlson, Mannheimer, and Park references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) secured a partial victory over Omni MedSci's wearable health‑monitoring patent, finding 12 of the 23 claims unpatentable while leaving 11 claims intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple successfully invalidated Omni MedSci’s wearable pulse‑oximeter patent in a final PTAB decision, finding all 23 claims unpatentable for obviousness. The Board affirmed claim constructions and applied the petitioner’s alternative argument on the combination of prior‑art references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple successfully challenged Omni MedSci’s wearable health‑monitoring patent. The PTAB affirmed the claim construction and held all 23 claims obvious over prior art. No further briefing was authorized.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple, on behalf of Samsung, has filed an IPR petition challenging Omni MedSci’s ’533 wearable health‑monitoring patent. The petition asserts that the claims are obvious over prior‑art references Lisogurski, Carlson, and Mannheimer and requests that the Board institute the review.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) prevailed in IPR2020‑00175, with the PTAB finding all challenged claims of the ’299 wearable physiological‑monitoring patent unpatentable as obvious over Lisogurski, Carlson, Mannheimer and Park references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple has filed an IPR petition seeking to invalidate Omni MedSci’s ’484 wearable health‑monitoring patent. The petition asserts that the claims are obvious over a suite of prior‑art references covering optical sensing, AI processing and cloud connectivity. Apple requests that the Board institute the trial and find all claims unpatentable.
Samsung Electronics Co., Ltd. et al. v.Radian Memory Systems LLC
Samsung and Radian have reached a confidential settlement and jointly moved to terminate the inter partes review of U.S. Patent 11,347,657, arguing that the proceeding is at an early stage and termination serves public policy and efficiency.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) seeks to invalidate Omni MedSci’s ’533 wearable health‑monitoring patent, asserting that the claims are obvious over Lisogurski, Carlson, and Mannheimer. The petition requests the PTAB to institute an IPR and cancel the claims.
Microsoft Corporation v.Dialect, LLC
A statistical study of 192 IPR final written decisions from 2021 shows that patents invalidated in IPR have far more prior‑art citations and often depend on new evidence such as expert testimony. The findings suggest that post‑grant challenges frequently introduce prior art outside the examiner’s original search scope.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR petition challenges Omni MedSci’s ’484 wearable health‑monitoring patent, asserting that all 23 claims are obvious over a combination of prior‑art references. The petition seeks institution and a finding of unpatentability.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Samsung and Apple have filed an IPR petition challenging Omni MedSci’s ’533 patent covering wearable optical health monitors. The petition asserts obviousness over Lisogurski, Carlson, and Mannheimer references and asks the Board to institute the review and cancel the claims.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple has filed an IPR petition seeking to invalidate Omni MedSci’s ’484 wearable health‑monitoring patent. The petition argues the claims are obvious over a combination of five prior‑art references and requests that the Board institute the trial.
Microsoft Corporation v.Dialect, LLC
Microsoft and Dialect reached a confidential settlement, leading the PTAB to terminate the IPR before trial. The Board granted the joint motion and ordered the settlement to remain confidential.
Microsoft Corporation v.Dialect, LLC
Microsoft and Dialect reached a settlement that resolves disputes over patent 8,620,659 and other patents, leading to a joint motion to terminate the inter partes review before the Board makes an institution decision.
Microsoft Corporation v.Dialect, LLC
Microsoft and Dialect have jointly moved to keep their settlement agreement confidential, invoking trade‑secret protections under the CFR. The motion seeks Board‑only access and notification of any disclosure requests.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple seeks to invalidate Omni MedSci’s wearable health‑monitor patent, arguing that all challenged claims are obvious over prior art. The petition requests the PTAB to institute an IPR and cancel the claims.
Microsoft Corporation v.Dialect, LLC
The PTAB denied Microsoft’s petition for an inter partes review of five patents owned by Dialect, LLC, exercising discretion under 35 U.S.C. § 314(a). The Board cited the patents’ age, subsidiary ownership, and a parallel district court case as reasons to avoid duplication.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) prevailed on 12 of the 23 challenged claims of Omni MedSci’s wearable physiological monitoring patent, finding them obvious over multiple prior‑art references. The remaining claims were left unpatentable pending further proof.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.